倒卖医保回流药遭严打，仍有中介活跃在朋友圈，手续费45%，“连10万元的都刷过，一两万元都不算大额”

Core Viewpoint - The National Healthcare Security Administration (NHSA) has intensified efforts to combat the illegal trade of "returned drugs," leading to a significant reduction in their availability in pharmacies and online platforms [1][8][10]. Group 1: Regulatory Actions - The NHSA has launched a comprehensive crackdown on the resale of returned drugs, with over 50 articles published on this issue in the past year [1]. - The implementation of a collaborative enforcement mechanism involving multiple departments, including public security and market regulation, marks a significant advancement in combating the issue [10]. - The introduction of a new monitoring module in the unified healthcare information platform allows for real-time tracking of returned drugs, involving both insured individuals and healthcare providers in the regulatory loop [10]. Group 2: Market Response - Many pharmacy owners are now avoiding returned drugs due to heightened penalties and the fear of criminal charges, resulting in a noticeable decrease in their presence in both physical and online pharmacies [8][10]. - Despite the crackdown, some intermediaries continue to exploit loopholes, particularly in private social networks, where advertisements for drug buybacks are still prevalent [11][14]. Group 3: E-commerce Challenges - E-commerce platforms remain a significant area for the sale of returned drugs, with complaints still being reported despite a reduction in overall incidents [18]. - The lack of pre-transaction scrutiny on e-commerce platforms makes it challenging to identify and prevent the sale of returned drugs, as the platforms primarily focus on compliance with seller qualifications rather than the actual products sold [18][20]. Group 4: Legal Implications - The legal framework surrounding the resale of returned drugs is becoming clearer, with potential criminal charges for those involved in fraudulent activities related to healthcare funds [20][23]. - Consumers who purchase returned drugs can pursue legal action for compensation, with specific pathways outlined for cases involving defective or returned drugs [24][26].